Is Vista Pharmaceuticals Ltd (524711) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Vista Pharmaceuticals Ltd is a below average quality company .

Is Vista Pharmaceuticals Ltd (524711) undervalued or overvalued?

The key valuation ratios of Vista Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Vista Pharmaceuticals Ltd (524711) share price return in the past 10 years?

Vista Pharmaceuticals Ltd share price has declined -6.5% annually (CAGR) over the past ten years.

Is Vista Pharmaceuticals Ltd (524711) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Vista Pharmaceuticals Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the share price of Vista Pharmaceuticals Ltd (524711)?

Company share prices are keep on changing according to the market conditions. The current trading price of Vista Pharmaceuticals Ltd (524711) on 30-Apr-2026 16:59:59 at 16:59 is 7.74.

What is the P/E ratio of Vista Pharmaceuticals?

The latest standalone P/E ratio of Vista Pharmaceuticals as of 30-Apr-2026 is 0.00.

What is the P/B ratio of Vista Pharmaceuticals Ltd (524711)?

The latest standalone P/B ratio of Vista Pharmaceuticals Ltd (524711) as of 30-Apr-2026 is 1.13.

What is the 52-week high and low of Vista Pharmaceuticals Ltd (524711)?

The 52-week high of Vista Pharmaceuticals Ltd (524711) is Rs. 12.01 and the 52-week low is Rs. 5.71.

Vista Pharmaceuticals Ltd (524711) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Vista Pharmaceuticals Ltd (524711)
Brand: Vista Pharmaceuticals

Vista Pharmaceuticals Ltd (524711) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Vista Pharmaceuticals Ltd (524711)

BSE: 524711 NSE:

Key Metrics

Market Cap

₹48 Cr.

P/E Ratio

0.00

Price to Book (P/B)

1.13

Price to Sales (P/S)

5.52

EV/EBITDA

-7.05

Return on Capital Employed (ROCE)

-8.54%

Current Price

₹7.7

Return on Equity (ROE)

-11.47%

Return on Assets (ROA)

-8.41%

Operating Profit Margin

-38.6%

Net Profit Margin

-46.14%

Gross Profit Margin

-45.2%

Book Value per Share

₹6.9

Sales Growth (YoY)

-2.14%

Sales Growth (3 Years)

195.57%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

N/A%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹6 / 12

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

21.19%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1 Stock return of Vista Pharmaceuticals Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of -6.5% based on the current price.

Q.1 Revenue growth of Vista Pharmaceuticals Ltd?

Vista Pharmaceuticals Ltd revenue growth is -2.1% for FY-2025, which is above its 5-year CAGR of -15.05%, indicating faster growth.

Q.1 Which industry/sub-sector does Vista Pharmaceuticals Ltd belong to?

Vista Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.1 Promoter shareholding and pledge status of Vista Pharmaceuticals Ltd?

Promoters hold 21.19% of the Vista Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Vista Pharmaceuticals Ltd vs industry peers?

Vista Pharmaceuticals Ltd revenue CAGR is -15.05%, compared to the industry median CAGR of 8.30%, indicating slower growth and losing its market share.

DeciZen - make an informed investing decision on Vista Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Vista Pharmaceuticals stock performance

Key Ratios

Is Vista Pharmaceuticals Ltd an attractive stock to invest in?

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	9.6%	8.9%	12.4%	6.3%	-5.2%	-5.1%	-3.8%	-9.6%	-8.3%	-8.5%	-
Value Creation Index ⓘ	-0.3	-0.4	-0.1	-0.6	-1.4	-1.4	-1.3	-1.7	-1.6	-1.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	15.4	24.2	28.9	31.1	22.8	1.3	0.4	1	10.3	10.1	9
Sales YoY Gr.	-	57.2%	19.6%	7.4%	-26.8%	-94.4%	-69.3%	156.4%	929%	-2.1%	-
Adj EPS ⓘ	0.4	0.5	0.7	0	-1.3	-0.6	-0.2	-1.5	-1	-0.8	-1.3
YoY Gr.	-	34.3%	48.9%	-100%	NA	NA	NA	NA	NA	NA	-
BVPS (₹) ⓘ	4.5	6.3	9	11	9.8	8.9	9.6	8.1	7.6	7.4	6.9
Adj Net Profit ⓘ	0.9	1.3	2	0	-3.8	-2	-0.9	-5.6	-4.5	-4.6	-8
Cash Flow from Ops. ⓘ	-2.5	2.6	-4.6	3.3	0.8	-6.8	-1	-1.7	-4.9	-7	-
Debt/CF from Ops. ⓘ	-3.2	4.4	-2.4	3.4	19.3	-1.6	-12.6	-5.8	-1.6	-1.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-4.6%	-15.1%	195.6%	-2.1%
Adj EPS ⓘ	-208.8%	NA	NA	NA
BVPSⓘ	5.7%	-5.4%	-8.5%	-2.4%
Share Price	-6.5%	-10%	-4.8%	-30.1%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	8	9	8.4	0	-11.6	-6.4	-2.5	-15.4	-11.6	-10.8	-17.5
Op. Profit Mgn % ⓘ	17.7	12.6	18.5	4	-21.1	-136.6	-306.8	-386.9	-33.4	-38.6	-98.1
Net Profit Mgn % ⓘ	5.6	5.2	7	0	-16.6	-158.6	-215.1	-552.7	-43.4	-45.9	-89.2
Debt to Equity ⓘ	0.7	0.7	0.4	0.3	0.5	0.3	0.4	0.3	0.2	0.2	-
Working Cap Days ⓘ	332	270	290	287	351	6,408	21,738	8,671	878	937	346
Cash Conv. Cycle ⓘ	95	52	59	153	249	3,977	13,580	6,495	313	213	45

Recent Performance Summary

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	-1.3	-
TTM Sales (₹ Cr.)	8.6	-
BVPS (₹) ⓘ	6.9	-
Reserves (₹ Cr.) ⓘ	30	-
P/BV ⓘ	1.13	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	5.71 / 12.01
All Time Low / High (₹)	0.08 / 56.15
Market Cap (₹ Cr.)	47.6
Equity (₹ Cr.)	12.3
Face Value (₹)	2
Industry PE ⓘ	43.4

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Vista Pharma - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	15.38	24.18	28.92	31.07	22.76	1.27	0.39	1	10.29	10.07
Operating Expenses ⓘ +	12.78	21.13	23.58	29.84	27.56	3	1.66	5.32	13.84	14.10
Manufacturing Costs	1.18	0.93	1.63	0.84	1.85	0.42	0.29	0.38	1.05	1.03
Material Costs	9.57	16.10	15.96	25.41	22.97	0.73	0.37	2.83	8.89	8.35
Employee Cost	0.81	0.70	0.87	1.18	1.31	1.15	0.57	0.51	1.79	2
Other Costs ⓘ	1.22	3.40	5.11	2.40	1.43	0.69	0.43	1.60	2.10	2.72
Operating Profit ⓘ	2.60	3.06	5.34	1.24	-4.80	-1.73	-1.27	-4.32	-3.55	-4.03
Operating Profit Margin (%)	16.9%	12.6%	18.5%	4.0%	-21.1%	-136.0%	-321.0%	-430.0%	-34.5%	-40.0%
Other Income ⓘ +	0.02	0.06	0.40	2.95	3.75	0.20	0.17	0.40	0.33	0.44
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.77	0.88	1.57	1.67	1.54	1.55	0.90	1.34	1.24	0.97
Depreciation ⓘ	1.02	1.02	1.34	1.36	1.35	0.73	0.62	0.62	0.72	0.74
Profit Before Tax ⓘ	0.84	1.22	2.83	1.15	-3.94	-3.81	-2.62	-5.88	-5.18	-5.29
Tax ⓘ	0.06	-0.02	0.64	0.21	-0.26	-1.80	-1.73	-0.21	-0.67	-0.64
Profit After Tax	0.77	1.25	2.19	0.94	-3.68	-2.01	-0.89	-5.66	-4.51	-4.65
PAT Margin (%)	5.0%	5.2%	7.6%	3.0%	-16.2%	-158.0%	-225.0%	-564.0%	-43.9%	-46.1%
Adjusted EPS (₹)	0.3	0.5	0.8	0.3	-1.2	-0.6	-0.2	-1.5	-1.0	-0.8
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	11.21	16.61	26.29	33.32	29.64	32.84	35.45	30.55	35.65	45.41
Share Capital ⓘ	5	5.31	5.83	6.07	6.07	7.36	7.36	7.51	9.43	12.31
Reserves ⓘ	6.21	11.29	20.46	27.25	23.57	25.49	28.09	23.04	26.22	33.10
Debt +	7.88	11.33	11.06	11.17	15.47	10.71	12.55	9.96	7.96	7.40
Long Term Debt	7.88	6.03	5.88	5.96	5.51	8.69	7.43	5.18	2.93	2.38
Short Term Debt	0	5.30	5.18	5.21	9.96	2.02	5.13	4.78	5.03	5.02
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	6.55	12.93	9.13	5.25	5.16	5.11	5.37	7.80	7.41	5.59
Others Liabilities ⓘ	0.74	0.15	6.23	2.90	0.47	3.94	-1.26	5.07	3.65	-2.49
Total Liabilities ⓘ	26.38	41.03	52.71	52.64	50.74	52.61	52.11	53.39	54.67	55.92
Fixed Assets
Net Fixed Assets ⓘ +	9.96	13.46	17.67	20.52	20.66	19.93	19.33	19.74	19.32	18.70
Gross Block	18.74	14.47	20.02	24.24	25.72	25.72	25.74	26.76	27.06	27.18
Accumulated Depreciation	8.78	1.02	2.35	3.71	5.06	5.79	6.41	7.02	7.74	8.48
CWIP ⓘ	0	1.99	7.11	8.54	8.78	9.08	9.08	9.33	9.82	10.14
Investments ⓘ	0	0	0.02	0.03	0.02	0.04	0.03	0.02	0.02	0.05
Inventories	2.68	8.14	10.91	11.25	9.68	9.68	9.33	7.68	6.79	8.22
Trade Receivables	9.74	9.01	10.86	8.35	10.28	2.17	10.46	11.25	4.19	3.39
Cash Equivalents	0.43	5.77	1.79	0.87	0.23	0.14	0.07	0.20	0.09	0.73
Others Assets ⓘ	3.57	2.65	4.36	3.08	1.09	11.56	3.80	5.17	14.44	14.69
Total Assets ⓘ	26.38	41.03	52.71	52.64	50.74	52.61	52.11	53.39	54.67	55.92

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-2.50	2.57	-4.58	3.30	0.80	-6.75	-0.99	-1.71	-4.91	-6.98
PBT ⓘ	0.84	1.22	2.83	1.15	-3.94	-3.69	-2.62	-5.88	-5.18	-5.29
Adjustment ⓘ	1.78	1.88	2.61	2.03	1.91	2.25	1.51	1.83	1.94	1.73
Changes in Working Capital ⓘ	-4.93	-0.52	-10.03	0.5	2.83	-5.31	0.12	1.28	-1.68	-3
Tax Paid ⓘ	-0.18	0	0	-0.38	0	0	0	1.05	0	-0.43
Cash Flow From Investing Activity ⓘ +	-0.24	-3.61	-10.61	-5.65	-1.73	-0.30	-0.01	-1.27	-0.79	-0.44
Capex	-0.25	-3.64	-10.66	-5.65	-1.73	-0.30	-0.01	-1.27	-0.79	-0.44
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0.01	0.03	0.05	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	3.07	6.36	11.22	1.43	0.28	6.96	0.94	3.11	5.59	8.06
Net Proceeds from Shares ⓘ	0	3.78	7.49	0.24	0	9	0	0.76	9.61	14.39
Net Proceeds from Borrowing ⓘ	7.88	6.03	-0.15	0.07	-0.45	3.19	0.67	-2.25	-2.25	-0.55
Interest Paid ⓘ	-0.77	-0.88	-1.57	-1.67	-1.54	-1.55	-0.90	-1.21	-1.22	-0.96
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-4.04	-2.57	5.45	2.79	2.27	-3.68	1.16	5.81	-0.55	-4.81
Net Cash Flow ⓘ	0.34	5.32	-3.98	-0.92	-0.64	-0.09	-0.07	0.13	-0.11	0.64

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	7.15	8.97	10.19	3.15	-11.68	-6.43	-2.6	-17.16	-13.63	-11.47
ROCE (%)	9.57	8.92	12.42	6.28	-5.2	-5.1	-3.75	-9.58	-8.28	-8.54
Asset Turnover Ratio	0.63	0.72	0.62	0.59	0.44	0.02	0.01	0.02	0.19	0.18
PAT to CFO Conversion(x)	-3.25	2.06	-2.09	3.51	N/A	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	249.70	141.60	125.40	112.80	149.40	1,794.10	5,842.80	3,948.40	273.90	137.30
Inventory Days	34.40	81.70	120.30	130.10	167.80	2,790.40	8,791.50	3,091.80	256.60	271.80
Payable Days	272.70	220.80	252.20	103.30	82.70	2,566.30	5,213	849.70	312.20	284.30

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Vista Pharmaceuticals Ltd FAQs

The current trading price of Vista Pharma on 30-Apr-2026 16:59 is ₹7.74.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 29-Apr-2026 the market cap of Vista Pharma stood at ₹47.64 Cr

The latest P/E ratio of Vista Pharma as of 29-Apr-2026 is 0.00.

The latest P/B ratio of Vista Pharma as of 29-Apr-2026 is 1.13.

The 52-week high of Vista Pharma is ₹12.01 and the 52-week low is ₹5.71.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Vista Pharma is ₹8.63 ( Cr.) .

About Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Limited was incorporated on January 25,1991 under the Companies Act of 1956 with the Registrar of Companies Andhra Pradesh & has obtained Certificate of Commencement of Business on February 7, 1991. Vista Pharmaceuticals was incorporated by Dr. Dhananjaya Alli & his associates. The capital was subscribed by Vista Pharmaceuticals Inc., an Overseas Corporate Body promoted by them as a per the laws of State of New Jersy, United States of America.

The Company was in process of setting up a 100% EOU for manufcacture of drug formulations with an installed capacity of 400 million tablets & 200 million capsules per annum.

Vista, the largest division of Torrent Pharmaceuticals Ltd, offers a range of products mainly in the therapeutic areas of gastrointestinal, pain management and anti-infective, catering to common ailments. This division is a primary contributor to the domestic sales of Torrent Pharmaceuticals Ltd.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Vista Pharmaceuticals Ltd (524711) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Vista Pharma Share Price